Nomura monitors the performance and stock of Dr Lal PathLabs, noting sustained traction in the Delhi NCR market.
2 reports, 1 independent
Updated Jul 27
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nomura monitors the performance and stock of Dr Lal PathLabs, noting sustained traction in the Delhi NCR market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nomura
corporation in Japan
-
Dr Lal PathLabs
public company
Nothing else this week.
Related events
- Nomura maintained a 'Buy' rating on India's most valuable company.
- Nomura released analysis regarding the growth of Intellectual Property in India.
- Nomura, Torrent Pharmaceuticals, and JB Pharma reported various financial updates, including growth in India and acquisition synergies.
- Nomura provided financial analysis regarding Nasdaq options.
- Nomura maintained a neutral rating on Bank of Baroda shares.
Coverage
Newest first; wire copies grouped- indiatimes.comDr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?
- indiatimes.com